查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433662

In vivo CRO 市场规模、份额和趋势分析报告：按模型类型、模式、适应症、GLP 类型、地区和细分市场进行预测，2024-2030 年

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type (Non GLP, GLP Toxicology), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 257 Pages | 商品交期: 2-10个工作天内

价格

In vivo CRO 市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球体内CRO市场规模将达到79.3亿美元，预测期内复合年增长率为8.1%。

新兴国家医药市场的成长、对多种体内细胞疗法的强劲需求、材料科学的快速发展以及药物-器械组合的复杂性正在推动该地区的服务需求。此外，体内临床前和临床研究的增加、监管部门的核准、市场参与企业服务的扩展以及各种疾病负担都对市场收益做出了贡献。此外，新兴经济体增加低成本临床前和临床服务外包是支持体内 CRO 市场成长的关键因素之一。

同样，越来越多的药品境外外包到新兴经济体也创造了​​巨大的市场需求。已开发国家的预算审查、价格压力和报销制度的变化是预计印度和中国等新兴国家药品赞助商更多采用成本控制措施的一些关键因素。在新兴国家，将临床前体内服务等开发服务外包给合约服务供应商预计将增加对品质保证和监管服务的需求，从而促进对体内外包服务的需求增加。 FDA核准的严格流程以及欧盟地区的监管变化预计将使欧洲的核准流程复杂化。这些都是促使製药公司境外外包到新兴国家的主要因素。

COVID-19 大流行最初对临床试验行业产生了负面影响，但体内 CRO 市场也受到了负面影响。生物製药产业将重点转向开发针对 COVID-19 的疫苗和治疗方法，这产生了意想不到的后果，可能会扰乱其他疾病的临床试验。细胞和基因治疗行业的公司面临的主要挑战之一是无法在所需的临床试验地点及时为患者提供治疗。此外，基于细胞的疗法的提供在大流行后带来了一些挑战。由于担心 SARS-CoV-2 传播，尤其是针对弱势群体，医院对提供细胞治疗服务犹豫不决。由于封锁和旅行禁令，患者无法前往细胞治疗中心。

此外，主要参与企业正在参与併购、合作伙伴关係、协议、联盟和服务推出等策略，以扩大其全球足迹和服务/产品系列。例如，2023年4月，PsychoGenics, Inc.宣布推出eCube，这是一个药理学脑电图平台，旨在增强表型药物发现。同样，2023年2月，百奥赛图宣布推出Nano 100计划，开发100多种针对特定标靶的全人奈米抗体药物。这项工作将百奥赛图专有的 RenNano（一种能够产生完全人类奈米抗体的小鼠模型）与先进的体外和体内抗体筛检平台结合。透过利用这些整合技术，百奥赛图有望促进全人奈米抗体药物的广泛开发。

in vivo CRO 市场报告亮点

  • 由于囓齿类动物在基因上与人类相似，因此对模型的需求持续不断，其中囓齿类动物细分市场占据了最大的销售份额，达到 81.8%。此外，它们体型小、生命週期短、易于维护和遗传资源丰富，使其成为体内 CRO 研究最受欢迎的动物物种。
  • 小分子领域在体内 CRO 市场中占据主导地位。这种增长是由候选药物开发中对小分子的需求所推动的。此外，小剂量小分子的高治疗功效正在推动这一领域的成长。
  • 2023年癌症领域的市场规模将是压倒性的巨大，主要成长因素包括癌症负担的增加、对新型基因疗法的需求迅速增加以及癌症免疫疗法的临床前试验。根据美国基因与细胞治疗协会的数据，大约 97% 的 CAR T 细胞疗法正在针对癌症适应症进行开发。
  • 由于各种针对脑部疾病的模型为基础的临床实验药物的功效，中枢神经系统疾病领域预计将出现最快的成长。
  • 由于根据特定指南进行的标准化测试的增加，GLP毒理学领域在2023年占据了最大的市场占有率。
  • 2023年，北美在vivo CRO市场中占据最大收益占有率，达到50.0%。该地区的成长归因于成熟市场参与者的存在、各种疾病负担的增加以及该地区对 CRO 的需求不断增长。其他成长要素包括研发活动、临床前试验和市场参与者创新的增加。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章体内 CRO 市场：变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • in vivo CRO市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析

第四章体内CRO市场：模型类型估算及趋势分析

  • 车型类型市场占有率，2023 年和 2030 年
  • 细分仪表板
  • 按模型类型分類的全球体内 CRO 市场前景
  • 2018年至2030年市场规模、预测与趋势分析

第五章 In vivo CRO市场：模态估计与趋势分析

  • 2023年及2030年医疗器材市场占有率
  • 细分仪表板
  • 按模式分類的全球体内 CRO 市场前景
  • 2018年至2030年市场规模、预测与趋势分析

第六章 Invivo CRO市场：适应症估计与趋势分析

  • 2023年及2030年指示市场占有率
  • 细分仪表板
  • 按适应症分類的全球体内 CRO 市场前景
  • 2018年至2030年市场规模、预测与趋势分析

第七章体内CRO市场：GLP类型估算及趋势分析

  • 2023年及2030年GLP类型市场占有率
  • 细分仪表板
  • 以 GLP 类型分類的全球体内 CRO 市场前景
  • 2018年至2030年市场规模、预测与趋势分析

第八章体内CRO市场：区域估算与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • IQVIA Inc.
    • Crown Bioscience
    • Taconic Biosciences, Inc.
    • PsychoGenics Inc.
    • Evotec
    • Janvier Labs
    • Biocytogen Boston Corp
    • GemPharmatech
    • Charles River Laboratories
    • Icon Plc
    • Labcorp Drug Development
    • Parexel International Corporation
    • SMO Clinical Research（I）Pvt Ltd.
Product Code: GVR-1-68038-011-8

In Vivo CRO Market Growth & Trends:

The global in vivo CRO market size is expected to reach USD 7.93 billion by 2030, registering a CAGR of 8.1% during the forecast period, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights:

  • The rodent-based segment held the largest revenue share of 81.8% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
  • The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
  • The oncology segment dominated the market in 2023, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
  • The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
  • The GLP toxicology segment accounted for the largest market share in 2023 owing to the increasing number of standardized studies conducted according to specific guidelines
  • North America held the largest revenue share of 50.0% in in-vivo CRO market in 2023. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Model Type
    • 1.2.2. Modality
    • 1.2.3. Indication
    • 1.2.4. GLP Type
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Model type outlook
    • 2.2.2. Modality outlook
    • 2.2.3. Indication outlook
    • 2.2.4. GLP type outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Changing regulatory landscape
      • 3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
      • 3.2.1.3. Rising demand for advanced products
      • 3.2.1.4. Implementation of international standards by contract manufacturers
      • 3.2.1.5. Rising price competition and requirement to reduce cost
      • 3.2.1.6. Increasing complexity concerning product design and engineering
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Compliance issues while outsourcing
      • 3.2.2.2. Changing scenarios in developing countries
      • 3.2.2.3. Regulatory and legal compliance
      • 3.2.2.4. Contractual obligation
  • 3.3. In Vivo CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. In Vivo CRO Market: Model Type Estimates & Trend Analysis

  • 4.1. Model Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global In Vivo CRO Market by Model Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Rodent based
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Rat models
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Mice models
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Others
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non-rodent based
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In Vivo CRO Market: Modality Estimates & Trend Analysis

  • 5.1. Modality Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global In Vivo CRO Market by Modality Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Small molecules
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Large molecules
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Cell & gene therapy
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.2. CAR T-cell therapies
      • 5.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.3. CAR-NK cell therapies
      • 5.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.4. TCR-T cell therapies
      • 5.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.5. Other (Includes- TCR-NK, CARM, and TAC-T)
      • 5.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. RNA therapy
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis

  • 6.1. Indication Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global In Vivo CRO Market by Indication Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oncology
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Blood cancer
      • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Solid tumor
      • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2. Solid tumor
      • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.2. Syngeneic model
      • 6.4.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.3. Patient derived xenograft
      • 6.4.1.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.4. Xenograft
      • 6.4.1.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.3. Others
      • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. CNS conditions
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. Epilepsy
      • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. Parkinson's disease
      • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. Huntington's disease
      • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.5. Stroke
      • 6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.6. Muscular dystrophy
      • 6.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.7. Alzheimer's disease
      • 6.4.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.8. Traumatic brain injury
      • 6.4.2.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.9. Amyotrophic lateral sclerosis (ALS)
      • 6.4.2.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.10. Spinal muscular atrophy
      • 6.4.2.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.11. Muscle regeneration
      • 6.4.2.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.12. Other neurodevelopment disorders
      • 6.4.2.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Diabetes
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Obesity
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Pain management
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.5.2. Chronic pain
      • 6.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.5.3. Chronic pain
      • 6.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Autoimmune/inflammation conditions
      • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.2. Rheumatoid arthritis
      • 6.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.3. Multiple sclerosis
      • 6.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.4. Osteoarthritis
      • 6.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.5. Irritable bowel syndrome
      • 6.4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.6. Others
      • 6.4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Others
      • 6.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis

  • 7.1. GLP Type Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global In Vivo CRO Market by GLP Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. GLP toxicology
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Non GLP
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. IQVIA Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Crown Bioscience
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Taconic Biosciences, Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. PsychoGenics Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Evotec
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Janvier Labs
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Biocytogen Boston Corp
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. GemPharmatech
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Charles River Laboratories
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Icon Plc
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Labcorp Drug Development
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Parexel International Corporation
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. SMO Clinical Research (I) Pvt Ltd.
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America in vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 4 North America in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 5 North America in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 6 North America in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 7 U.S. in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 8 U.S. in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 9 U.S. in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S. in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 11 Canada in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 12 Canada in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 13 Canada in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Canada in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 15 Europe in vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 17 Europe in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 18 Europe in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Europe in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 20 Germany in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 21 Germany in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 22 Germany in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 23 Germany in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 24 UK in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 25 UK in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 26 UK in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 27 UK in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 28 France in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 29 France in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 30 France in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 31 France in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 32 Italy in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 33 Italy in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 34 Italy in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Italy in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 36 Spain in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 37 Spain in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 38 Spain in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 39 Spain in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 40 Denmark in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 41 Denmark in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 42 Denmark in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 43 Denmark in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 44 Sweden in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 45 Sweden in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 46 Sweden in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Sweden in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 48 Norway in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 49 Norway in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 50 Norway in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Norway in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific in vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 57 China in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 58 China in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 59 China in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 60 China in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 61 Japan in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 62 Japan in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 63 Japan in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 64 Japan in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 65 India in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 66 India in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 67 India in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 68 India in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 69 South Korea in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 70 South Korea in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 71 South Korea in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 72 South Korea in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 73 Australia in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 74 Australia in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 75 Australia in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 76 Australia in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 77 Thailand in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 78 Thailand in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 79 Thailand in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 80 Thailand in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 81 Latin America in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 82 Latin America in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 83 Latin America in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 84 Latin America in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 85 Brazil in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 86 Brazil in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 87 Brazil in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 88 Brazil in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 89 Mexico in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 90 Mexico in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 91 Mexico in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 92 Mexico in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 93 Argentina in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 94 Argentina in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 95 Argentina in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 96 Argentina in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 97 MEA in vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 99 MEA in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 100 MEA in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 101 MEA in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 102 South Africa in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 103 South Africa in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 104 South Africa in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 105 South Africa in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 110 UAE in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 111 UAE in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 112 UAE in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 113 UAE in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 114 Kuwait in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 115 Kuwait in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 116 Kuwait in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 117 Kuwait in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 In vivo CRO market: market outlook
  • Fig. 14 In vivo CRO competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 In vivo CRO market driver impact
  • Fig. 20 In vivo CRO market restraint impact
  • Fig. 21 In vivo CRO market strategic initiatives analysis
  • Fig. 22 In vivo CRO market: Model type movement analysis
  • Fig. 23 In vivo CRO market: Model type outlook and key takeaways
  • Fig. 24 Rodent based market estimates and forecast, 2018 - 2030
  • Fig. 25 Rat models estimates and forecast, 2018 - 2030
  • Fig. 26 Mice Models market estimates and forecast, 2018 - 2030
  • Fig. 27 Others estimates and forecast, 2018 - 2030
  • Fig. 28 Non-rodent based market estimates and forecast, 2018 - 2030
  • Fig. 29 In vivo CRO Market: Modality movement Analysis
  • Fig. 30 In vivo CRO market: Modality outlook and key takeaways
  • Fig. 31 Small molecules market estimates and forecasts, 2018 - 2030
  • Fig. 32 Large molecules market estimates and forecasts,2018 - 2030
  • Fig. 33 Cell & gene therapy market estimates and forecasts,2018 - 2030
  • Fig. 34 CAR T-cell therapies market estimates and forecasts, 2018 - 2030
  • Fig. 35 CAR-NK cell therapy market estimates and forecasts, 2018 - 2030
  • Fig. 36 TCR-T cell therapy market estimates and forecasts, 2018 - 2030
  • Fig. 37 Other (Includes- TCR-NK, CARM, and TAC-T) market estimates and forecasts, 2018 - 2030
  • Fig. 38 RNA therapy market estimates and forecasts, 2018 - 2030
  • Fig. 39 Others market estimates and forecasts, 2018 - 2030
  • Fig. 40 In vivo CRO market: Indication movement analysis
  • Fig. 41 In vivo CRO market: Indication outlook and key takeaways
  • Fig. 42 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 43 Blood cancer market estimates and forecasts,2018 - 2030
  • Fig. 44 Solid tumor market estimates and forecasts, 2018 - 2030
  • Fig. 45 Syngeneic model market estimates and forecasts,2018 - 2030
  • Fig. 46 Syngeneic model market estimates and forecasts, 2018 - 2030
  • Fig. 47 Xenograft market estimates and forecasts,2018 - 2030
  • Fig. 48 Others market estimates and forecasts,2018 - 2030
  • Fig. 49 CNS conditions market estimates and forecasts,2018 - 2030
  • Fig. 50 Epilepsy market estimates and forecasts,2018 - 2030
  • Fig. 51 Parkinson's disease market estimates and forecasts,2018 - 2030
  • Fig. 52 Huntington's disease market estimates and forecasts,2018 - 2030
  • Fig. 53 Stroke market estimates and forecasts,2018 - 2030
  • Fig. 54 Muscular dystrophy market estimates and forecasts,2018 - 2030
  • Fig. 55 Alzheimer's disease market estimates and forecasts,2018 - 2030
  • Fig. 56 Traumatic brain injury market estimates and forecasts,2018 - 2030
  • Fig. 57 Amyotrophic lateral sclerosis (ALS) market estimates and forecasts,2018 - 2030
  • Fig. 58 Spinal muscular atrophy market estimates and forecasts,2018 - 2030
  • Fig. 59 Muscle regeneration market estimates and forecasts,2018 - 2030
  • Fig. 60 Other neurodevelopment disorders market estimates and forecasts,2018 - 2030
  • Fig. 61 Diabetes market estimates and forecasts,2018 - 2030
  • Fig. 62 Obesity market estimates and forecasts,2018 - 2030
  • Fig. 63 Pain management market estimates and forecasts,2018 - 2030
  • Fig. 64 Chronic pain market estimates and forecasts,2018 - 2030
  • Fig. 65 Acute pain market estimates and forecasts,2018 - 2030
  • Fig. 66 Autoimmune/inflammation conditions market estimates and forecasts,2018 - 2030
  • Fig. 67 Rheumatoid arthritis market estimates and forecasts,2018 - 2030
  • Fig. 68 Multiple sclerosis market estimates and forecasts,2018 - 2030
  • Fig. 69 Osteoarthritis market estimates and forecasts,2018 - 2030
  • Fig. 70 Irritable bowel syndrome market estimates and forecasts,2018 - 2030
  • Fig. 71 Others market estimates and forecasts,2018 - 2030
  • Fig. 72 Others market estimates and forecasts,2018 - 2030
  • Fig. 73 Global in vivo CRO market: Regional movement analysis
  • Fig. 74 Global in vivo CRO market: Regional outlook and key takeaways
  • Fig. 75 Global in vivo CRO market share and leading players
  • Fig. 76 North America market share and leading players
  • Fig. 77 Europe market share and leading players
  • Fig. 78 Asia Pacific market share and leading players
  • Fig. 79 Latin America market share and leading players
  • Fig. 80 Middle East & Africa market share and leading players
  • Fig. 81 North America, by country
  • Fig. 82 North America
  • Fig. 83 North America market estimates and forecasts, 2018 - 2030
  • Fig. 84 U.S.
  • Fig. 85 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 86 Canada
  • Fig. 87 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 88 Europe
  • Fig. 89 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 90 UK
  • Fig. 91 UK market estimates and forecasts, 2018 - 2030
  • Fig. 92 Germany
  • Fig. 93 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 94 France
  • Fig. 95 France market estimates and forecasts, 2018 - 2030
  • Fig. 96 Italy
  • Fig. 97 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 98 Spain
  • Fig. 99 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 100 Denmark
  • Fig. 101 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 102 Sweden
  • Fig. 103 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 104 Norway
  • Fig. 105 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 106 Asia Pacific
  • Fig. 107 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 108 China
  • Fig. 109 China market estimates and forecasts, 2018 - 2030
  • Fig. 110 Japan
  • Fig. 111 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 112 India
  • Fig. 113 India market estimates and forecasts, 2018 - 2030
  • Fig. 114 Thailand
  • Fig. 115 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 116 South Korea
  • Fig. 117 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 118 Australia
  • Fig. 119 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 120 Latin America
  • Fig. 121 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 122 Brazil
  • Fig. 123 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 124 Mexico
  • Fig. 125 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 126 Argentina
  • Fig. 127 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 128 Middle East and Africa
  • Fig. 129 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 130 South Africa
  • Fig. 131 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 132 Saudi Arabia
  • Fig. 133 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 134 UAE
  • Fig. 135 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 136 Kuwait
  • Fig. 137 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 138 Market share of key market players- In vivo CRO market